SEC 13F Intelligence

Managers / Q1 2020 · view latest →

Burrage Capital Management LLC

CIK 0001796461 · 314 COMMONWEALTH AVENUE, #4, BOSTON, MA, 02115 · 617-410-4770

Reported Value
$102M
Q1 2020
Positions
31
Filings on Record
8
2020–present window
Filed
May 14, 2020
original filing

Summary

Burrage Capital Management LLC reported $102M in U.S.-listed holdings across 31 positions for Q1 2020.

Its largest position, Epizyme, represents 12.3% of the portfolio.

Compared with Q4 2019, the fund opened 9 new positions and exited 7.

Portfolio Metrics

Turnover
+20.1%
vs prior filed quarter
Top-10 Concentration
+57.9%
share of reported value
Largest Position
+12.3%
Epizyme
New / Exited
9 / 7
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’19: $149MQ4 ’19Q1 ’20: $102MQ1 ’20Q2 ’20: $143MQ2 ’20Q3 ’20: $127MQ3 ’20Q4 ’20: $131MQ4 ’20Q1 ’21: $123MQ1 ’21Q2 ’21: $100MQ2 ’21Q3 ’21: $0Q3 ’21filingsflow.com

Portfolio Composition

By security type
Common Stock: 90.5%Other: 9.4%ADR: 0.1%
  • Common Stock · 90.5% · $92M
  • Other · 9.4% · $10M
  • ADR · 0.1% · $84,000

Quarter-over-Quarter Changes full breakdown →

vs Q4 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CYTKCYTOKINETICS INCNEW+318.3K318.3K+$4M$4M
RGNXREGENXBIO INCNEW+115.0K115.0K+$4M$4M
AVROBIO INCNEW+225.9K225.9K+$3M$3M
TURNING PT THERAPEUTICS INCNEW+77.2K77.2K+$3M$3M
XENEXENON PHARMACEUTICALS INCNEW+200.0K200.0K+$2M$2M
ZOGENIX INCNEW+70.0K70.0K+$2M$2M
AIMTAIMMUNE THERAPEUTICS INCNEW+112.5K112.5K+$2M$2M
IRWDIRONWOOD PHARMACEUTICALS INCNEW+115.9K115.9K+$1M$1M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2020

31 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1EPIZYME INCCOM12.34%$13M893.7K
2PTCTPTC THERAPEUTICS INChistory →COM8.03%$8M181.2K
3KIDSORTHOPEDIATRICS CORPhistory →COM6.57%$7M171.1K
4NEONEOGENOMICS INChistory →COM5.16%$5M192.3K
5IVERIC BIO INCCOM4.91%$5M1.52M
6ANABANAPTYSBIO INC COMhistory →COM4.41%$4M331.9K
7MEI PHARMA INCCOM4.40%$4M3.02M
8Y-MABS THERAPEUTICS INCCOM4.34%$4M171.8K
9CRNXCRINETICS PHARMACEUTICALS INChistory →COM3.96%$4M282.3K
10G1 THERAPEUTICS INCCOM3.83%$4M378.1K
11CYTKCYTOKINETICS INChistory →COM3.56%$4M318.3K
12RGNXREGENXBIO INChistory →COM3.48%$4M115.0K
13CTMXCYTOMX THERAPEUTICS INChistory →COM3.41%$3M483.0K
14CARA THERAPEUTICS INCCOM3.24%$3M258.8K
15AVROBIO INCCOM3.22%$3M225.9K
16TURNING PT THERAPEUTICS INCCOM3.20%$3M77.2K
17FREQUENCY THERAPEUTICS INCCOM2.96%$3M173.9K
18AUPHAURINIA PHARMACEUTICALS INChistory →COM2.86%$3M196.4K
19TRICIDA INCCOM2.74%$3M131.7K
20XENEXENON PHARMACEUTICALS INChistory →COM2.08%$2M200.0K
21APELLIS PHARMACEUTICALS INCCOM2.01%$2M74.5K
22ZOGENIX INCCOM1.63%$2M70.0K
23AIMTAIMMUNE THERAPEUTICS INChistory →COM1.58%$2M112.5K
24ADVERUM BIOTECHNOLOGIES INCCOM1.53%$2M156.0K
25AERIE PHARMACEUTICALS INCCOM1.17%$1M88.4K
26IRWDIRONWOOD PHARMACEUTICALS INChistory →COM1.15%$1M115.9K
27INSMINSMED INCCOM0.99%$1M65.4K
28WVEWAVE LIFE SCIENCES LTDCOM0.55%$556,00056.7K
29ADURO BIOTECH INCCOM0.36%$363,000135.9K
30SUNESIS PHARMACEUTICALS INCCOM0.28%$280,000682.6K
31AUTLAUTOLUS THERAPEUTICS LTDSPON ADS0.08%$84,00015.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2021$01Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$100M22Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$123M27May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$131M25Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$127M27Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$143M26Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$102M31May 14, 202013F-HRchanges · EDGAR ↗
Q4 2019$149M29Feb 14, 202013F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.